Literature DB >> 1983344

Loss of acid suppression during dosing with H2-receptor antagonists.

C Wilder-Smith1, F Halter, T Ernst, M Gennoni, B Zeyen, L Varga, J J Roehmel, H S Merki.   

Abstract

The suppression of intragastric acidity with H2-receptor antagonists may diminish with repeated administration. To assess the degree and dose-dependence of this tolerance after short-term dosing, two doses of the H2-receptor antagonists, ranitidine (300 mg nocte or q.d.s.) and sufotidine (300 mg or 600 mg b.d.), were given to healthy volunteers for 1 and 2 weeks, respectively. After 1 and 7 days of dosing with ranitidine 300 mg q.d.s. the median 24-h and night-time pH, measured by continuous 24-h pH-metry, dropped from 3.7 to 2.2 and 5.8 to 3.2, respectively (P less than 0.0001 for both). The decline in median pH with ranitidine 300 mg nocte was only significant during the night (from 4.1 to 2.9) (P less than 0.04). There was little change in plasma gastrin concentrations between days 1 and 7 with either dosage. With sufotidine 300 mg b.d. and 600 mg b.d. for 1 and 14 days, the median 24-h pH fell from 3.7 to 2.1 and from 4.6 to 2.6, respectively (P less than 0.0001). The equivalent medians for the night decreased from 6.3 to 2.3 and from 6.6 to 3.1 (P less than 0.0001). Gastrin concentrations did not change after 14 days of dosing with sufotidine 300 mg b.d., but increased significantly during dosing with sufotidine 600 mg b.d. (P less than 0.001). Significant tolerance developed in 7-14 days and it seemed to show some dose relationship. The mechanisms behind tolerance and the role of gastrin are discussed, but remain unclear.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1983344

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

1.  pH-feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses.

Authors:  C H Wilder-Smith; F Halter; W Häcki; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

Review 2.  Treatment of gastroesophageal reflux disease.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

3.  Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.

Authors:  C U Nwokolo; J T Smith; A M Sawyerr; R E Pounder
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

4.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

5.  New method for long-term monitoring of intragastric pH.

Authors:  Shouko Ono; Mototsugu Kato; Yuji Ono; Masahiro Asaka
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

6.  Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Authors:  Tomohiko Shimatani; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

7.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

Review 8.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

9.  Expression patterns of transforming growth factor-beta and its receptors in gastric mucosa of patients with refractory gastric ulcer.

Authors:  Shou-Chuan Shih; Kwang-Wen Tseng; Shee-Chan Lin; Chin-Roa Kao; Sun-Yen Chou; Horng-Yuan Wang; Wen-Hsiung Chang; Cheng-Hsin Chu; Tsang-En Wang; Chung-Liang Chien
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

10.  The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.

Authors:  Dominic-Luc Webb; Tobias Rudholm-Feldreich; Linda Gillberg; Md Abdul Halim; Elvar Theodorsson; Gareth J Sanger; Colin A Campbell; Malcolm Boyce; Erik Näslund; Per M Hellström
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-24       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.